Hetero, the global API leader, has consolidated its position as the partner of choice of the pharmaceutical industry in Mexico, with a portfolio of more than 300 APIs. GM Gurulinga Konanuris is piloting entry into the B2C market, with upcoming launches of biosimilars, oncology and HIV treatments. Hetero is also investing more than USD 50 million in the country to develop its manufacturing capacity of high-specialty products.
You were recently appointed GM of Hetero Mexico. What attracted you to embark on this new challenge?
The growth trajectory of Hetero, which was only founded in 1993, is absolutely mind-blowing. After only two decades in the market, the group displayed global sales of USD 1.5 billion in 2015.
